Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Tourlite Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Tourlite returned -4.6% in Q1 2025 while maintaining cautious positioning around 30% net exposure. The fund focuses on event-driven longs like Sable Offshore and FTAI Infrastructure while shorting overvalued consumer companies."
Tourlite Fund returned -4.6% in Q1 2025, maintaining a cautious stance with average net beta-adjusted exposure of 30%. The manager increased net exposure in March as market selloffs created attractive risk-reward opportunities, primarily by covering higher-beta short positions. Key long positions include Sable Offshore, which is restarting offshore oil production with expected sales beginning in July, and FTAI Infrastructure, approaching a fundamental inflection with EBITDA expected to double to $300 million. The biotech special situations portfolio continues to offer meaningful mispricing opportunities across companies like Roivant and Grail. On the short side, the fund targets overvalued consumer discretionary and staples companies facing rising input costs and weakening demand. Trump's tariff policies create macro uncertainty, with the manager seeing two likely outcomes: stagflation or demand-driven recession. The resurgence of low-quality businesses in AI, quantum computing, and crypto sectors presents compelling short opportunities for the second half of 2025.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager demonstrates high conviction in specific positions like FTAI Infrastructure (over 100% upside potential) and Sable Offshore, with detailed fundamental analysis. They also show strong conviction in their biotech special situations thesis and consumer shorts strategy, backed by specific catalysts and reasoning.
Growth Outlook
The manager expresses caution about market conditions, citing Trump's tariff policies, weakening economic signals like dollar weakness and rising bond yields, and expecting either stagflation or recession. However, they also acknowledge tactical opportunities and potential for Fed easing in certain scenarios.
Risk Appetite
The fund increased net exposure to 30% in March, covering higher-beta shorts and taking advantage of market selloffs. While maintaining a cautious overall stance, they are selectively deploying capital in attractive opportunities like biotech special situations and event-driven longs.
Capital Deployment
The fund increased net exposure from lower levels to 30% in March by covering shorts, representing moderate deployment. However, they maintain a cautious overall stance with net exposure in the 20-30% range, suggesting selective rather than aggressive deployment.
Forward Guidance
The manager sees compelling opportunities ahead, particularly in shorting low-quality businesses in frothy sectors and continuing to hold biotech special situations. They express optimism about specific holdings like FTAI Infrastructure and Sable Offshore, though acknowledge macro headwinds.
Language Signal
Language is balanced with both risk-focused terms (overextended, astronomical valuations, fragile economy) and opportunity-focused terms (compelling opportunities, meaningful mispricing, attractive entry points). The net balance is slightly cautious but not overwhelmingly negative.
Perceived Risk
The manager identifies multiple significant risks including tariff-driven inflation, potential stagflation or recession, dollar weakness, and systemic risks from overvalued sectors like AI and crypto. They maintain defensive positioning and acknowledge substantial macro uncertainty.
Opportunity Density
The manager sees selective opportunities in biotech special situations, event-driven longs, and shorting overvalued sectors. While not describing a broad opportunity set, they identify specific compelling areas with meaningful mispricing and upcoming catalysts.
Time Horizon
The investment approach focuses on fundamental inflection points and long-term value realization, particularly in biotech special situations and infrastructure plays. The manager references multi-year catalysts and emphasizes patience in waiting for intrinsic value recognition, suggesting a medium to long-term orientation.
